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AbstractA new principle of a method for the laboratory diagnosis of latent Mycobacterium tuberculosis infection (LBTI) compared to the QuantiFERON (QFT) test is presented.  The new elements, the calculation and introduction of an Index of Stimulation (IS) were 
based on the measurements of tumour necrosis-α (TNF-α) release in whole human blood stimulated by the peptides (TB-P) derived from Mycobacterium tuberculosis (Mtb) related proteins and Purified 
Protein Derivative (PPD). The amount of TNF-α was determined by ELISA. The calculation of IS values was carried by the formula: TNF-
α(pg/ml)TB-P/ TNF-α(pg/ml)PPD. The populations studied consisted of a) 15 healthcare workers dealing with Mtb- infected patients (HCW-TB); b) 14 healthcare workers not being exposed to Mtb patients (HCW-C) as controls. The diagnosis of LTBI was established if IS was 
higher than 1.50. In the HCW-TB group the number of LTBI was 6/15 
by the new method and 9/15 by QFT. Tested clinically, the number of 
false-positive results by QFT was 3/9. All members of HCW-C group were LTBI negative by both methods. This new assay did not result in any false positive reactions. Although these results are still preliminary data derived from few patients. However, the theoretical novelties in 
the principle of method: the calculation of IS from the TNF-α-TB-P/ 
TNF-α –PPD values can mean a progress in the individual laboratory diagnosis of LTBI in further studies.   
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IntroductionA great number of studies have been reported on markers that can differentiate between active tuberculosis disease (TB) caused by Mycobacterium tuberculosis (Mtb) and latent tuberculosis infection (LTBI) from the “clinically” healthy population [1]. The disease affects both Bacillus Calmette-Guérin (BCG)-vaccinated and non-vaccinated people and susceptibility to infection and disease is related to decreased host immunity. Traditionally, the diagnosis of LTBI has relied on the tuberculin skin test (TST, Mantoux reaction) [2]. However, it has several limitations, including a high rate of false-positive results among individuals vaccinated with BCG or exposed to non-TB Mycobacteria [3]. 
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Genome driven advances in Mtb antigen discovery have 
identified antigens that are absent from the M. bovis BCG. These antigens are encoded by open reading frames distributed in 12 regions of difference (RD) on the MTB chromosome, and offer the advantage to distinguish between infection and prior vaccination with BCG. RD1 based ESAT-6 (Rv3875) and CFP-10 (Rv3874), both of which form the basis of the two recently commercialised immunodiagnostic tests: T-SPOT.TB and QuantiFERON-TB-Gold [4-7]. Regardless of their reported sensitivities, the T-cell based 
Interferon γ (IFN γ) Release Assays (IGRAs) are dominating for the diagnosis of LTBI [7-9]. Typically, cocktails of ESAT-6, CFP-10 and peptide 38-55 from TB.7.7 (Rv2654c) derived from 
M. tuberculosis have been applied in these measurements to stimulate the peripheral mononuclear cells to produce antigen 
specific release of IFN γ.However, the two types of commercially available IGRA tests: a) “QuantiFERON-TB Gold In Tube (QFT” and 
b) “TSPOT.TB” have not shown sufficient diagnostic accurateness [7, 10]  “Currently, there is no gold standard for TB screening and the most-used diagnostic tools show low agreement”[11]. However, it is also true that there are new efforts to identify the potential biomarkers from the supernatants of samples of IGRA test. It became apparent from these studies that among the great number 
of newly identified compounds and the “classic” biomarker (IFN 
γ), tumour necrosis alpha (TNF-α) was always detectable as one of the key molecules for Mycobacterial dormancy and host responses in tuberculosis [12-16]. In the current work we report on the calculation and introduction of a stimulation test with Mycobacterium related 
peptides including three basic modifications: 
a) Using TNF-α measurements instead of IFN γ.b) Evaluating the stimulating effect of a synthetic peptide mixture 
(TB-P) in comparison to “Purified Protein Derivative” (PPD). 
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c) Definition and use of an Index of Stimulation (IS) value. We compared this new type of measurement with QFT 
focusing on the laboratory verification of LTBI in healthcare workers dealing with TB patients for a long time (HCW-TB), as well as in healthcare workers not being exposed to TB patients as controls (HCW-C). The TB-P cocktail used in this study contained synthetic overlapping peptides derived from ESAT-6 and CFP-10 proteins applied   also in the QFT assay in order to concentrate only 
on the difference between the cytokines released: TNF-α versus 
IFN γ. Since all individuals of the present study have earlier been vaccinated by BCG (derived from Bacillus Mycobacterium bovis), 
PPD (cell- free purified protein fraction obtained from a human strain of Mycobacterium tuberculosis) was used as the “control” stimulant versus TB-P. PPD was chosen in order to reduce the chance of false positivity compared to the values of stimulation by TB-P. It is known, however, that the previous BCG vaccinations 
can cause numerous false positive Mantoux reactions induced by PPD [17]. Therefore, in our experimental design we always used also PPD stimulation taking possible to calculate an “Index of 
Stimulation (IS)”. Thus, by the calculation of IS, the non-specific 
“background” effects of PPD could be eliminated from the specific effects of TB-P. 
Materials and Methods
Synthesis and Chemical Characterization of ESAT-6 and 
CFP-10 Peptide Series
All peptides were synthesized with Fmoc/tBu solid phase method using Rink Amide MBHA resin resulting in peptide amide N-terminus. The characterization of the peptides by mass 
spectrometry and amino acid analysis confirmed the expected composition and their cytotoxicity and stability also were tested [18&19]. The peptides are presented in Table 1.
Table 1: Chemical characterization of CFP-10 and ESAT-6 synthetic peptides
Sequence Code RP-HPLC
retention time 
[min]a
Mav
calculated/
measuredb
Aminoacid Analysisc
1MAEMKTDAATLAQEAGNFERISGDL25 C1 28.7 2668.9/2668.4 D 3.49  [3]; T 1.72 [2]; S 1.05 [1]; E 4.20 [4];G 1.93 [2]; A 5.13 [5]; V 3.05 [3]; I 1.05 [1]; L 1.68 [2];F 0.92 [1];  K 1.05 [1]; R 0.80 [1]16GNFERISGDLKTQIDQVESTAGSLQ40 C2 27.6 2692.9/2693.1 D 2.67  [3]; T 1.95 [2]; S 3.13 [3]; E 5.74 [5];G 3.07 [3]; A 1.28 [1]; V 1.03 [1]; I 1.69 [2]; L 2.00 [2];F 0.97 [1]; K 0.87 [1]; R 0.62 [1]30DQVESTAGSLQGQWRGAAGTAAQAAV55 C3 22.4 2529.7/2529.2 D 0.63  [1]; T 1.95 [2]; S 1.68 [2]; E 4.32 [5];G 4.18 [4]; A 8.04 [7]; V 1.86 [2]; L 0.95 [1]; R 0.77 [1]46AAGTAAQAAVVRFQEAANKQKQELD73 C4 26.2 2614.9/2615.1 D 1.99  [2]; T 0.92 [1]; E 7.03 [6];G 0.76 [1]; A 8.25 [8]; V 2.08 [2]; L 1.10 [1];F 1.05 [1];  K 1.89 [2]; R 0.89 [1]56AANKQKQELDEISTNIRQAGVQYSR80 C5 24.6 2847.1/2847.3 D 2.79  [3]; T 1.03 [1]; S 2.23 [2]; E 6.22 [6];G 1.27 [1]; A 3.37 [3]; V 1.14 [1]; I 1.73 [2]; L 1.00 [1];Y 0.83 [1]; K 1.71 [2]; R 1.68 [2]71IRQAGVQYSRADEEQQQALSSQMGF95 C6 22.8 2827.1/2826.8 D 1.36  [1]; S 2.81 [3]; E 8.86 [8];G 1.86 [2]; A 3.27 [3]; V 1.00 [1];  M 0.55 [1];  I 0.68 [1];L 1.00 [1]; Y 0.91 [1];  F 1.17 [1]; R 1.45 [2]1MTEQQWNFAGIEAAASAIQG20 E1 29.8 2122.3/2122.0 D 1.24 [1]; T 0.96 [1]; S 0.96 [1]; E 5.44 [5];G 1.93 [2]; A 5.22[5]; M 0.56 [1];  I 1.69 [2];F 1.15 [1]; R 1.45 [2]10GIEAAASAIQGNVTIS25 E2 32.4 1500.7/1500.8 D 1.15  [1]; T 0.99 [1]; S 2.04 [2]; E 2.02 [2];G 2.12 [2]; A 4.15 [4]; V 1.02 [1]; I 2.74 [3]16SAIQGNVTSIHSLLDEGKQSLTKLA40 E3 28.1 2609.9/2609.7 D 1.75  [2]; T 1.96 [3]; S 3.76 [3]; E 3.00 [3];G 2.11 [2]; A 2.16 [2]; V 1.03 [1];  I 1.44 [2];L 4.28 [4]; H 1.08 [1];  K 2.42 [2]31EGKQSLTKLAAAWGGSGSEAYQGVQ55 E4 24.1 2522.8/2522.7 T 1.04 [1]; S 2.72 [3]; E 5.24 [5];G 4.50 [5]; A 3.85 [4]; V 0.93 [1];L 1.78 [2]; K 1.94 [2]46SGSEAYQGVQQKWDATATELNNALQ80 E5 26.9 2708.9/2709.0 D 2.95  [3]; T 1.86 [2]; S 1.66 [2]; E 6.81 [6];G 1.86 [2]; A 4.00 [4]; V 1.00 [1]; L 2.00 [2];Y 0.76 [1];  K 1.09 [1]61TATELNNALQNLARTISEAGQAMAS85 E6 37.4 2574.9/2574.6 D 3.07  [3]; T 2.96 [3]; S 2.08 [2]; E 4.66 [4];G 0.92 [1]; A 6.27 [6]; M 0.46 [1];  I 0.92 [1];L 3.00 [3]; R 0.88 [1]
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72NLARTISEAGQAMASTEGNVTGMFA95 E7 28.2 2526.8/2526.6 D 2.29  [2]; T 2.82 [3]; S 2.04 [2]; E 3.10 [3];G 2.98 [3]; A 5.12 [5]; M 1.56 [2]; V 1.02 [1]; I 1.02 [1]; L 0.89 [1];F 0.93 [1]; R 1.82 [2]aConditions: Knauer, Eurospher-100 C18 column (4.0 x 250 mm), 5 mm silica (pore size:300 Å), 
gradient elution: 5-60% B, 35 min, eluents: 0.1% TFA/ (A), 0.1% TFA/acetonitrile/water = 80/20 v/v (B), flow rate: 1.0 ml/min,
detection: l = 220, 214 nm bESI-MS (acquired by Bruker Esquire 3000+ ESI-MS).cHidrolysis (6M HCl, 110 0C, 24-36 hrs, Asn and Gln determined as Asp and Glu) 
Study populations 15 volunteers, healthcare workers, (11 women, 4 men, age: 28-61 years) dealing with TB patients or with their test materials at the Department of Pulmonology at the University of Debrecen 
and 2 HCW workers with verified LTBI  from Budapest (HCW-TB) as positive controls.  b) 14 healthcare workers not being exposed to TB patients as negative controls (10 women, 4 men, age: 31-67 years)(HCW-C). All participants in the study have been BCG-vaccinated in childhood.   
Ethical statementAll members of the study population signed a written consent to take part in the study. The number of ethical permission to carry out the examination is 30052-2015 emitted by the local Committee of Ethics at the University of Debrecen.
Sample handling7 ml of heparinized whole blood samples applicable for functional cellular tests were taken and used from every subject. The mononuclear cells (monocytes and lymphocytes) of blood were the targets of stimulation by TB-P and PPD [20]. 
a) Based on preliminary studies the final concentration of TB-P 
was 20μg/ml solved in a culture medium (RPMI-1640 plus 
10% FCS) and it was used as the specific stimulant. This dose of the peptides was not found cytotoxic on peripheral blood mononuclear cells (PBMC) of healthy donors [21]. 
b) The final concentration of Purified Protein Derivative (PPD) 
(Roche Diagnostics, Switzerland) was also 20μg/ml solved in the culture medium (RPMI-1640 plus 10%FCS).  This dose of PPD also was not found cytotoxic.
c) QuantiFERON-TB Gold In –Tube test ( QFT) (Cellestis, Australia) was used according to the manufacturer’s instructions. T-SPOT.TB ELISPOT assay was not used.
The verification of LTBI: was “classically” based on “positive” 
Mantoux and/or Quantiferon tests and a “negative” radiological lung result.  Patients with active tuberculosis were ruled out from this study.  
Cytokine measurement
The amount of tumour necrosis TNF-α was determined by the commercial ELISA kit purchased form R&D Systems (San Francisco, USA) carried out according to the description of the kit. 
Culturing and stimulation of the whole blood cells The cocktail of TB peptides and PPD were used as stimulants for the whole blood samples of HCW-TB and HCW-C groups simultaneously as follows:       1 ml of fresh heparinized blood (in duplicated tubes) Activating agents: 
a) PPD: 20μg/ml; 
b) TB peptides: 20μg/ml; c) Control: the same volume of culture medium (RPMI-1640 plus 10% FCS)Incubation: 20 hours at 37o C grade, 5% CO2 milieu   
The measurement of TNF-α by ELISA occurred in the centrifuged plasma samples.
The diagnosis of LTBI established by the calculation of 
Index of Stimulation 
Index of Stimulation (IS): TNFα (pg/ml)TB/ TNFα (pg/ml)
PPD. The diagnosis of existing LTBI: IS > 1.50 . This value was chosen after the analysis of the data of Table 2, as the value of 1.61 was not only clinically positive for LTBI but also by QFT. Thus, the value of 1.50 can be a safe border to separate the “positive” and “negative” cases.    No LTBI: IS < 1.50
 Borderline: IS = 1.50 (clinically “positive”)
 The name of assay: “TNFα–IS Test” (Tumour Necrosis Factor 
α- Index of Stimulation Test) 
The results of QFT measurementsThe QFT tests were used according to the protocol at the 
Department of Microbiology carried out in parallel to “TNFα – IS Test”.The evaluation of QFT results:   
IFN γ  <0.35 IU: negative
IFN γ > 0.35 IU: positive
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Statistical analysis
The Spearman’s coefficient of correlation (r) was calculated 
between the results of the “TNFα – IS” and QFT tests. 
P < 0.05 was considered significant.  
Results
Comparison of results on TNF-α release induced by 
PPD and TB peptides with the results of QuantiFERON 
test in blood samples of HCW-TBIn a series of preliminary experiments we investigated the 
blood samples of two healthcare workers as “positive” controls with existing LTBI from the National Tuberculosis Centre of Budapest dealing with TB patients for decades in comparison with two healthy “negative” control subjects. In these studies 
we found the dose of 20μg/ml of peptide cocktail/protein to be the optimal amount for stimulations by both TB peptides and PPD. In addition, it became also clear that the changes found by 
measurement of TNF-α were only able to reflect LBTI compared to 
IL -1β, IL-6 and IL-10. Furthermore, the “20 hours” as   incubation time was also more practical than that of 4, 12 and 24 hours. (Data are not shown).
Table 2: Comparison of results on TNF-α release induced by PPD and TB peptide cocktail with the results of QuantiFERON  test in blood samples of HCW-TB
Code
Cells
(pg/ml)
Cells+
PPD
(pg/ml)
Cells+           
TB-P
(pg/ml)
TNFα-IS
(TB-P/PPD)
QFT Coincidence 
(Y/N)
HCW-TB1     (n.t) 1.4 10.6 17.1 1.61 pos. YHCW-TB2     (n.t) 0.7 2.5 20.5 8.20 pos. YHCW-TB3     (h) 5.3 5.9 16.3 7.76 pos. YHCW-TB4     (n.t) <0.2 <0.2 80.6 >403 pos. YHCW-TB5     (h) <0.2 15.2 50.3 3.31 pos. YHCW-TB6     (n)* <0.2 <0.2 <0.2 <1.50 pos. NHCW-TB7     (n) <0.2 <0.2 <0.2 <1.50 neg. YHCW-TB8     (n) <0.2 <0.2 <0.2 <1.50 neg. YHCW-TB9     (h)* <0.2 <0.2 0.2 <1.50 pos. NHCW-TB10   (n) <0.2 <0.2 <0.2 <1.50 neg. YHCW-TB11   (h)* <0.2 <0.2 <0.2 <1.50 pos. NHCW-TB12   (a) <0.2 <0.2 <0.2 <1.50 neg. YHCW-TB13   (a) <0.2 145.5 <0.2 <1.50 neg. YHCW-TB14   (n) <0.2 <0.2 <0.2 <1.50 neg. YHCW-TB15  (n.t) <13.3 17.0 36.7 2.15 pos. Y
PPD: Purified Protein Derivative                                               Result of Mantoux-test:TB-P: TB-Peptide                                                                            (n): normerg
TNFα-IS: Index of Stimulation                                                    (h): hyperergQFT: QuantiFERON TB Gold I-Tube                                          (a): anergY: Yes                                                                               N: No                                                                                                (n.t): Mantoux not testedPos: Positive                                                                                      * false positivity in QFTNeg: Negative                                                 HCW-TB: health care worker dealing with Mtb patients                                            
Table 2, shows the coincidence between the data of TNF-α measurements and Quantiferon test in the case of 15 HCW-TB patients.  Based on 13 YES (Y) and 3 NO (N), the “value of coincidence” (V.C) was 80 %. Namely, among the healthcare workers dealing with Mtb patients HCW-TB6, HCW-TB9 and HCW-TB11 were found to be “positive” by QFT for LTBI, but they were 
“negative” using the TNF-α-IS Test. The Spearman’s coefficient 
of correlation r=0.667 (P = 0.007) was also highly significant between the results of two methods, showing a remarkable 
accordance. However, it was very important that the accordance was highly not perfect between the two methods. The number of 
positive cases was higher measured by QFT (9/15) than by TNF-
α-IS Test (6/15). The 3 persons (HCW-TB6, HCW-TB9 and HCW-TB11) not showing the coincidence have been clinically further tested for LTBI, and they were found to be “negative”. Thus, their QFT results could be regarded as “false positive laboratory 
findings”. Two of these individuals showed hyperactivity and one normal Mantoux reaction. 
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Comparison of results on TNF-α release induced by 
PPD and TB peptides with the results  of  QuantiFERON 
test in blood samples of HCW-CAll the 14 members of control subjects (HCW-C) were negative 
by both methods for LTBI.  The “values of coincidence” (V.C) was 100% (Table 3). 
Table 3: Comparison of the results on TNF-α release induced by PPD and TB peptide cocktail with the results of QuantiFERON test in blood samples of HCW-C
Code Cells
(pg/ml)
Cells+PPD
(pg/ml)
Cells+ TBP
(pg/ml)
TNFα-IS
(pg/ml)
QFT Coincidence 
(Y/N)HCW-C1 <0.2 <0.2 <0.2 <1.50 neg. YHCW-C2 <0.2 <0.2 <0.2 <1.50 neg. YHCW-C3 <0.2 <0.2 <0.2 <1.50 neg. YHCW-C4 <0.2 <0.2 <0.2 <1.50 neg. YHCW-C5 <0.2 3.5 0.8 <1.50 neg. YHCW-C6 <0.2 <0.2 <0.2 <1.50 neg. YHCW-C7 9.8 4.9 4.3 <1.50 neg. YHCW-C8 15.3 13.3 14.3 <1.50 neg. YHCW-C9 <0.2 4.6 0.9 <1.50 neg. YHCW-C10 <3.9 4.9 4.3 <1.50 neg. YHCW-C11 <0.2 46.4 6.6 <1.50 neg. YHCW-C12 <0.2 3.6 <0.2 <1.50 neg. YHCW-C13 39.0 7.9 7.9 <1.50 neg. YHCW-C14 3.3 3.6 2.9 <1.50 neg. Y
PPD: Purified Protein Derivative                                               TB-P: TB-Peptide                                                                            
TNFα-IS: Index of Stimulation                                                        QFT: QuantiFERON TB Gold I-Tube                                             Y: Yes                                                                               Neg: NegativeHCW-C: health care worker control not dealing with Mtb patients
DiscussionIn the last years it became clear that the IGRA assays based on 
IFN γ release to diagnose LTBI performed insufficiently [7,10&11]. There is a need for new differential diagnostic methods. In the current work we developed a new approach and methodical principle for this purpose preserving one crucial element of QFT, namely, we used also a mixture of ESAT-6 and CFP-10 overlapping peptides to stimulate the mononuclear cells of whole blood, but only for 20 hours. At the same time, we are aware of the weakness of this study, not having a great number of determinations yet, being only at the beginning of a promising work.In the new assay four elements have been introduced and 
applied:  a) the release of TNF-α induced by TB-P was measured; b) in parallel, also PPD was used for cell stimulation as control; c) an Index of Stimulation named “IS” was calculated according to the formula: TNF-α TB-peptide (pg/ml)/ TNF-α PPD (pg/
ml)/; d.) if the IS  value was higher than 1.50 (IS > 1.50), the diagnosis of LTBI was established according to the data of Table 2.  We tested the two methods on healthcare workers dealing (HCW-TB) and not dealing with tuberculosis patients (HCW-C). 
Comparing the results of QFT and “TNF-α- IS” tests in HCW-TB subjects, the “value of coincidence” (VC) was rather good, 80 %. 
In addition, the Spearman’s coefficient of correlation r=0.667 (P 
= 0.007) was also highly significant between the results of two methods showing a remarkable parallel outcome. However, it was 
of note that in this group the rate of positivity was 9/15 by QFT, 
whereas it was 6/15 using the “TNF-α IS” test. Clinically, the 3 persons of discordance were negative for LTBI, thus they could be regarded as “false positive” cases found by QFT. Therefore, the great individual clinical importance of this observation is that these subjects would still get the chance for a biological 
therapy according to the “TNF-α-IS Test”.  This result shows 
that the specificity of the new measurement seems to be higher than that of QFT or Mantoux reaction. However, using the skin test, two of the three “false positive” patients gave “hyperergic” reactions. This phenomenon could be explained by the common 
IFN γ dependent mechanism of QFT and Mantoux tests [22]. At 
the same time, this fact also could reflect the different pathway 
of the “TNF-α” based approach. From these data the “values of coincidence”(V.C.)  were as follows:
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V.C. = Mantoux - “TNF-α -IS”: 66.66 %;                  
V.C. = Mantoux-QFT: 85.7 %In the new principle PPD was introduced as the “background” 
in the comparisons to the specific effects of TB-peptides. However, in Hungary but also in a rather great part of the world the effects of BCG vaccinations is rather strong in the majority of population. In the new assay, PPD as a standard basic stimulant can show 
the influence of the earlier BCG vaccinations reflected as a non-
specific release of TNF-α. Finally, calculating the IS values this background effect can be eliminated from the results of TB-P 
giving the values of true Mtb specificity.  This approach was able 
to differentiate between the specific (TB-P) and not specific (PPD) effects pointing out also the “false positive” part of QFT results.There is a long list of articles describing the increased 
production of TNF-α during LTBI [12-16]. Therefore, the choice of its measurement as a marker for the laboratory diagnosis of LTBI seems to be relevant. In addition, there can be still another 
theoretic advantage of “TNF-α-IS Test” to exclude LTBI before the 
“TNF-α targeted” biologic therapeutics [23&24].  We do think that 
the “TNF-α” character and the improved specificity of the new test may suggest a simple practical clinical message:  if the IS value is 
less than 1.50,   the TNF-α targeted biologic therapy can be started.” 
In our current work “TNFα – IS Test” was found superior than QFT in diagnosing LBTI in healthcare workers. These people represent that population which permanently would need a safe 
laboratory test for the diagnosis of LTBI [9&11].  The “TNFα – IS Test” can be offered also for them.In conclusion, we present here a new principle for a laboratory 
assay: the “TNFα – IS Test” developed for the laboratory diagnosis of LTBI and found superior compared to the QFT measurements. 
The efficacy of test was verified on healthcare workers dealing and not dealing with Mtb patients. Although the number of determinations is still not great. However, in further studies the theoretical novelties in the principle of method: the calculation of 
IS from the TNF-α-TB-P/ TNF-α –PPD values can mean a progress in the individual laboratory diagnosis of LTBI in patients before biological therapies and in the survey of healthcare workers dealing with Mtb patients.  
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